Scarica l'app Stockscreener
14.71
1.21%
-0.18
Dopo l'orario di chiusura:
14.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent
VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Insider Monkey
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc. (NASDAQ:VTRS) Q4 2025 Earnings Call Transcript - Insider Monkey
Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date - Finviz
JPMorgan Adjusts Price Target on Viatris to $17 From $16, Maintains Neutral Rating - marketscreener.com
A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update - Yahoo Finance
Viatris (VTRS) Quarterly Loss Of US$340.1 Million Tests Profitability Turnaround Narrative - Sahm
Decoding Viatris Inc (VTRS): A Strategic SWOT Insight - GuruFocus
Viatris Earnings: Drugmaker Left 2025 With Momentum; 2026 to Bring Stability and Broad-Based Growth - Morningstar
BofA raises Viatris stock price target on cost-cutting plan - Investing.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Is Strong Q4 Revenue And Steady Dividend Policy Altering The Investment Case For Viatris (VTRS)? - simplywall.st
Viatris Looks Well-Positioned for Durable Growth From New Launches and Cost Savings Initiatives - Morningstar
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Yahoo Finance
Earnings call transcript: Viatris Q4 2025 earnings beat forecasts, stock up - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan - Investing.com
Viatris Q4 2025 slides: earnings beat, major cost-cutting plan By Investing.com - Investing.com South Africa
Restructuring: Viatris to cut global workforce by about 10% - Pittsburgh Post-Gazette
Viatris Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025 - The Globe and Mail
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy - FinancialContent
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Viatris Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Viatris Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-02-26 - Seeking Alpha
Viatris forecasts 2026 profit below estimates on India manufacturing woes - marketscreener.com
Viatris Launches Major Restructuring After Strong 2025 Results - TipRanks
Viatris maintains annual dividend at 48 cents for 2026 - Investing.com
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2026 - marketscreener.com
Viatris Inc. Provides Earnings Guidance for the Fiscal Year 2026 - marketscreener.com
Viatris shares fall on lower-than-expected 2026 profit outlook - Investing.com Australia
Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% - Nasdaq
Viatris Q4 25 Earnings Conference Call At 8:30 AM ET - Nasdaq
Viatris beats on Q4; eyes 10% staff reduction (VTRS:NASDAQ) - Seeking Alpha
Viatris : VTRS Q4 2025 Earnings Presentation FINAL - marketscreener.com
Viatris : VTRS Q4 2025 Earnings Infographic - marketscreener.com
Viatris: Q4 Earnings Snapshot - marketscreener.com
Viatris beats estimates, stock edges up By Investing.com - Investing.com UK
Insights into Viatris Q4 Earnings - Benzinga
Viatris to cut up to 10% of staff as it targets $600M–$700M in savings - Stock Titan
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend - PR Newswire
Viatris Inc. Stock Nears 52-Week High Ahead of Q4 Earnings: Shares Climb on Pipeline Strength - International Business Times Australia
Global healthcare company Viatris Inc. recently disclosed that its pharmaceutical manufacturing facility in Nashik, India, has currently suspended production activities due to a fire incident that occurred in February this year. - Bitget
Key facts: FDA Accepts Viatris' MR-141 Application; Q4 Results Due Soon - TradingView
Investors await Viatris earnings amid cost-cutting optimism By Investing.com - Investing.com Nigeria
Viatris Q4 2025 Earnings Preview: Revenue Forecast & Analyst ExpectationsNews and Statistics - IndexBox
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drugs pipeline - Seeking Alpha
FDA accepts Viatris presbyopia treatment application - Investing.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - Seeking Alpha
FDA Accepts Viatris Inc. Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - marketscreener.com
1.75%
1.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):